Galapagos NV ( AMS:GLPG ) shareholders should be happy to see the share price up 13% in the last week. But will ...

Fintel reports that on February 14, 2025, Morgan Stanley downgraded their outlook for Galapagos NV - Depositary Receipt () ...

In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.

Galapagos NV (NASDAQ:GLPG) received FDA's IND clearance to begin clinical studies in the US for their CD19 CAR-T program, GLPG5101. The company reported strong clinical data from the ATLANTA study ...

Galapagos NV (GLPG) has been beaten down lately with too much selling pressure. While the stock has lost 21.2% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Galapagos (GLPG) stock dips as Morgan Stanley downgrades its rating to Underweight from Equal Weight amid its CAR-T therapy ...

Galapagos (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

Galapagos NV (GLPG) reports strong financials and strategic advancements amid increased R&D expenses and operational ...